The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Sep. 06, 2011
Filed:
Jul. 28, 2006
Kenneth Alan Simmen, Tervuren, BE;
Herman Augustinus DE Kock, Arendonk, BE;
Pierre Jean-marie Bernard Raboisson, Sterrebeek, BE;
Sandrine Marie Helene Vendeville, Woluwe-Saint-Pierre, BE;
Lili HU, Mechelen, BE;
Abdellah Tahri, Anderlecht, BE;
Dominique Louis Nestor Ghislain Surleraux, Braine-le-chateau, BE;
Wim Van DE Vreken, Beveren, BE;
Ismet Dorange, Ande, FR;
Yvan Simonnet, Rouen, FR;
Karl Magnus Nilsson, Grodinge, SE;
Bengt Bertil Samuelsson, Skarholmen, SE;
Asa Annica Kristina Rosenquist, Huddinge, SE;
Hans Kristian Wallberg, Hagersten, SE;
Kenneth Alan Simmen, Tervuren, BE;
Herman Augustinus De Kock, Arendonk, BE;
Pierre Jean-Marie Bernard Raboisson, Sterrebeek, BE;
Sandrine Marie Helene Vendeville, Woluwe-Saint-Pierre, BE;
Lili Hu, Mechelen, BE;
Abdellah Tahri, Anderlecht, BE;
Dominique Louis Nestor Ghislain Surleraux, Braine-le-chateau, BE;
Wim Van De Vreken, Beveren, BE;
Ismet Dorange, Ande, FR;
Yvan Simonnet, Rouen, FR;
Karl Magnus Nilsson, Grodinge, SE;
Bengt Bertil Samuelsson, Skarholmen, SE;
Asa Annica Kristina Rosenquist, Huddinge, SE;
Hans Kristian Wallberg, Hagersten, SE;
Tibotec Pharmaceuticals Ltd. Co, Cork, IE;
Medivir AB, Huddinge, SE;
Abstract
Inhibitors of HCV replication of formula (I) and the N-oxides, salts, and stereoisomers thereof, wherein each variable has specific definitions. Pharmaceutical compositions containing compounds (I) and process for preparing compounds (I) are also provided. Bioavailable combinations of the inhibitors of HCV of Formula (I) with ritonavir are also provided.